Mesenchymal stem cell-derived cell-free technologies: a patent landscape

Area of Science:

• Regenerative Medicine
• Biotechnology
• Intellectual Property Analysis

Background:

• Mesenchymal stem/stromal cells (MSC) are crucial for regenerative therapies.
• MSC-derived factors mimic MSC activity, leading to cell-free therapeutic approaches.
• Cell-free therapies are poised to potentially exceed traditional stem cell therapy.

Purpose of the Study:

• To analyze patent trends and R&D activities in MSC-derived cell-free products.
• To identify the state of the art, emerging technologies, and research trajectories.
• To assess the innovation landscape of cell-free regenerative medicine.

Main Methods:

• Patent literature search using Derwent World Patents Index™.
• Retrieved and analyzed 269 patent families related to MSC-derived cell-free products.
• Patent mapping to identify trends, applications, and technologies.

Main Results:

• An exponential increase in patent filings observed since the mid-2010s.
• Exosomes represent the primary focus of recent patent activity.
• Patents demonstrate diverse applications as medicinal agents and drug delivery systems.

Conclusions:

• MSC-derived cell-free products show rapidly growing innovation and R&D.
• Exosomes are a key area of development within cell-free regenerative medicine.
• Significant unexplored potential exists for cell-free technologies in various applications.